logo

Clinical Trial Calendar

Share
Results Date
Company Name
Ticker
Event
Indication
Outcome
Details
Q2 2018
Galmed Pharmaceuticals Ltd.
Topline data from phase 2b study of Aramchol (ARREST)
Nonalcoholic steatohepatitis or NASH
Q2 2018
Rexahn Pharmaceuticals inc.
Phase IIa data read-out of RX-3117
Metastatic Pancreatic Cancer (1st line treatment in combination with Abraxane)
Q2 2018
Axovant Sciences Ltd.
Top-line data from phase II study of Nelotanserin
REM Behavior Disorder in subjects with Lewy Body Dementia
Q2 2018
Audentes Therapeutics, Inc.
Preliminary data Phase 1 / 2 clinical study of AT342 (VALENS)
Crigler-Najjar
Mar 2018
ARCA biopharma, Inc.
Topline data from phase 2B trial of Gencaro (GENETIC-AF)
Treatment and prevention of recurrent atrial fibrillation o
Q1 2018
Eiger BioPharmaceuticals Inc.
Topline data from phase II study with Ubenimex (LIBERTY)
Pulmonary arterial hypertension
Jan 2018
Kala Pharmaceuticals, Inc.
Top-line results from Phase 3 trial of KPI-121 0.25%
Dry eye disease
Jan 2018
Revance Therapeutics, Inc.
Topline 8-week safety and efficacy Phase 2 results of of RT002 injectable
Plantar fasciitis
Jan 2018
SAGE Therapeutics, Inc.
Top line results from Part C of exploratory phase II clinical trial of SAGE-217
Essential tremor
before Q1 2018
Regenxbio Inc
Preliminary safety and tolerability data from phase I trial of RGX-314
Wet age-related macular degeneration
before Q1 2018
Regenxbio Inc
Preliminary safety and tolerability data from Phase I/II trial of RGX-501
Homozygous familial hypercholesterolemia
Jan 2018
VANDA PHARMACEUTICALS
Data from phase II study of HETLIOZ ( (2102)
Jet lag disorder
Q1 2018
VANDA PHARMACEUTICALS
Data from an 8-hour phase advance study of HETLIOZ (3107)
jet lag disorder
Jan 2018
BioLineRx Ltd.
Partial results from Phase 2a study of BL-8040 in combination with KEYTRUDA
Pancreatic cancer
Jan 2018
Pharma Mar S.A
PHMMF.OB
Data from phase 3 trial of Zepsyre (single agent)
Platinum resistant ovarian cancer
Jan 2018
Acceleron Pharma, Inc
Part 1 data of phase 2 study of ACE-083
Facioscapulohumeral muscular dystrophy (FSHD)
before Q1 2018
Audentes Therapeutics, Inc.
Preliminary clinical data from Phase 1 / 2 clinical study of AT132 (ASPIRO)
X-Linked Myotubular Myopathy (XLMTM)
Jan 2018
Axovant Sciences Ltd.
Topline data from phase 2b study of Intepirdine (HEADWAY)
Dementia with Lewy bodies
Jan 2018
Axovant Sciences Ltd.
Top-line data from Phase 2 study of Intepirdine
Gait and balance in subjects with Alzheimer’s disease, DLB and Parkinson’s disease dementia
Jan 2018
Axovant Sciences Ltd.
Top-line data from Phase 2 study of Nelotanserin
Lewy Body Dementia patients who experience frequent visual hallucinations
after Q1 2018
Biota Pharmaceuticals Inc.
Topline data from phase 2 trial of BTA074
Condyloma caused by human papillomavirus
after Q1 2018
BeyondSpring Inc.
Interim analysis of non-inferiority of phase 2/3 trial of Plinabulin ( Study 105)
Neutropenia
after Q1 2018
BeyondSpring Inc.
First data readout from phase 2/3 trial of Plinabulin ( Study 106)
Neutropenia
Q1 2018
Idera Pharmaceuticals, Inc.
Overall Response Rate data from phase 2 portion of Phase 1/2 trial of intratumoral IMO-2125
PD-1 refractory metastatic melanoma
Q1 2018
AVEO Pharmaceuticals, Inc.
Top line data from phase 3 trial of Tivozanib ( TIVO-3)
advanced renal cell carcinoma